Industry anger over stringent trial disclosure requirements | PDF (735 KB)

p527 | doi:10.1038/nrd2103

Safety concerns raised over RNA interference | PDF (296 KB)

p528 | doi:10.1038/nrd2104

Antibacterial drugs: New antibiotic on the horizon? | PDF (417 KB)

p539 | doi:10.1038/nrd2098

Neurological disorders: Homing in on the target of antidepressants | PDF (109 KB)

p540 | doi:10.1038/nrd2095

Liver disease: A new treatment for liver fibrosis? | PDF (81 KB)

p540 | doi:10.1038/nrd2096

Sepsis: Unpicking the pathogenesis of sepsis | PDF (109 KB)

p541 | doi:10.1038/nrd2097

Screening: Dirty drugs' secrets uncovered | PDF (89 KB)

p542 | doi:10.1038/nrd2099

Targeting signal transduction as a strategy to treat inflammatory diseases

Luke A. J. O'Neill

p549 | doi:10.1038/nrd2070

Recent advances in our understanding of the signalling pathways activated in inflammation have revealed several potential therapeutic targets. O'Neill reviews these pathways and speculates on the likelihood of drugs being developed that will limit inflammation without a deleterious impact on host defence.

• Abstract
• Full Text
• PDF (1,129 KB)

B cells move to centre stage: novel opportunities for autoimmune disease treatment

Jeffrey L. Browning

p564 | doi:10.1038/nrd2085

The recent success of the B-cell-depleting antibody rituximab — originally developed as a lymphoma therapy — in the treatment of rheumatoid arthritis has stimulated considerable interest in the potential of drugs that can modulate B-cell function to treat autoimmune disorders. Browning discusses the role of B cells in a range of such disorders and analyses approaches to therapeutic B-cell manipulation.

• Abstract
• Full Text
• PDF (358 KB)

Telomerase therapeutics for cancer: challenges and new directions

Jerry W. Shay & Woodring E. Wright

p577 | doi:10.1038/nrd2081

Telomerase is expressed by cancer cells where it contributes to tumour maintenance, but is absent from most normal cells. Strategies for targeting telomerase therefore provide new opportunities for targeted cancer therapy. Shay and Wright review the current status and future opportunities for telomerase therapeutics.

• Abstract
• Full Text
• PDF (491 KB)

Applications of ESI-MS in drug discovery: interrogation of noncovalent complexes

Steven A. Hofstadler & Kristin A. Sannes-Lowery

p585 | doi:10.1038/nrd2083

Mass spectrometry is emerging as a powerful analytical tool at various key stages in the drug discovery process. Hofstadler and Sannes-Lowery review the application of electrospray ionization mass spectrometry in the characterization of noncovalent complexes in drug discovery efforts against several classes of target.

• Abstract
• Full Text
• PDF (789 KB)

Drug discovery in the ubiquitin–proteasome system

Grzegorz Nalepa, Mark Rolfe & J. Wade Harper

p596 | doi:10.1038/nrd2056

The ubiquitin–proteasome pathway contains a large number of components that are possible drug targets for cancer and other diseases. Nalepa et al. review evidence linking components of this pathway to human disease and discuss potential strategies for therapeutic intervention.

• Abstract
• Full Text
• PDF (1,092 KB)